[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA28559B1 - Composes de quinolinone-carboxamide en tant qu'agonistes du recepteur de 5-ht4 - Google Patents

Composes de quinolinone-carboxamide en tant qu'agonistes du recepteur de 5-ht4

Info

Publication number
MA28559B1
MA28559B1 MA29423A MA29423A MA28559B1 MA 28559 B1 MA28559 B1 MA 28559B1 MA 29423 A MA29423 A MA 29423A MA 29423 A MA29423 A MA 29423A MA 28559 B1 MA28559 B1 MA 28559B1
Authority
MA
Morocco
Prior art keywords
receptor agonists
carboxamide compounds
quinolinone
quinolinone carboxamide
compounds
Prior art date
Application number
MA29423A
Other languages
English (en)
French (fr)
Inventor
Daniel Marquess
Paul R Fatheree
Derek S Turner
Daniel D Long
Seok-Ki Choi
Adam A Goldblum
Daniel Genov
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of MA28559B1 publication Critical patent/MA28559B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA29423A 2004-04-07 2006-10-30 Composes de quinolinone-carboxamide en tant qu'agonistes du recepteur de 5-ht4 MA28559B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56007604P 2004-04-07 2004-04-07

Publications (1)

Publication Number Publication Date
MA28559B1 true MA28559B1 (fr) 2007-04-03

Family

ID=34964334

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29423A MA28559B1 (fr) 2004-04-07 2006-10-30 Composes de quinolinone-carboxamide en tant qu'agonistes du recepteur de 5-ht4

Country Status (29)

Country Link
US (9) US7375114B2 (de)
EP (1) EP1735304B1 (de)
JP (2) JP4944012B2 (de)
KR (1) KR101167296B1 (de)
CN (1) CN100569771C (de)
AR (1) AR050407A1 (de)
AT (1) ATE420088T1 (de)
AU (1) AU2005233560B2 (de)
BR (1) BRPI0509761B8 (de)
CA (1) CA2561558C (de)
CY (1) CY1108908T1 (de)
DE (1) DE602005012249D1 (de)
DK (1) DK1735304T3 (de)
ES (1) ES2320907T3 (de)
HK (1) HK1099019A1 (de)
HR (1) HRP20090162T1 (de)
IL (1) IL178086A (de)
MA (1) MA28559B1 (de)
MX (1) MXPA06011398A (de)
MY (1) MY155036A (de)
NO (1) NO337126B1 (de)
NZ (1) NZ549941A (de)
PL (1) PL1735304T3 (de)
PT (1) PT1735304E (de)
RU (1) RU2394033C2 (de)
SI (1) SI1735304T1 (de)
TW (1) TWI351282B (de)
WO (1) WO2005100350A1 (de)
ZA (1) ZA200608363B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1486102A (en) * 2000-11-07 2002-05-21 Immunovaccine Technologies Inc Vaccines with enhanced immune response and methods for their preparation
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
JP5042028B2 (ja) * 2004-11-05 2012-10-03 セラヴァンス， インコーポレーテッド キノリノン−カルボキサミド化合物
WO2006052640A1 (en) * 2004-11-05 2006-05-18 Theravance, Inc. 5-ht4 receptor agonist compounds
EP1831211B1 (de) * 2004-12-22 2010-06-02 Theravance, Inc. Indazolcarbonsäureamidverbindungen
EA013567B1 (ru) * 2005-03-02 2010-06-30 Тереванс, Инк. Хинолиноновые соединения в качестве агонистов рецептора 5-ht
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
JP5086248B2 (ja) * 2005-06-07 2012-11-28 セラヴァンス， インコーポレーテッド ５−ｈｔ４受容体アゴニストとしてのベンゾイミダゾロン−カルボキサミド化合物
MY143574A (en) * 2005-11-22 2011-05-31 Theravance Inc Carbamate compounds as 5-ht4 receptor agonists
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
MX2008010555A (es) * 2006-02-16 2008-09-15 Theravance Inc Proceso para preparar intermediarios de compuestos agonistas de receptor de 5-ht4.
AU2008254999A1 (en) * 2007-05-17 2008-11-27 Theravance, Inc. Prokinetic agent for bowel preparation
TWI415850B (zh) 2007-07-20 2013-11-21 Theravance Inc 製備ｍｕ類鴉片受體拮抗劑之中間物的方法
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
NO2419104T3 (de) * 2009-04-13 2018-04-07
AU2009352490B2 (en) * 2009-09-14 2013-06-20 Suven Life Sciences Limited 1, 2-dihydro-2-oxoquinoline compounds as 5-HT 4 receptor ligands
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
US8835444B2 (en) 2010-02-02 2014-09-16 Novartis Ag Cyclohexyl amide derivatives as CRF receptor antagonists
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
BR112014026210A2 (pt) 2012-05-03 2017-06-27 Novartis Ag derivados de sal l-malato de 2,7-diaza-espiro[4.5]dec-7-il e formas cristalinas dos mesmos como agonistas do receptor de grelina
US11642339B2 (en) * 2017-07-31 2023-05-09 Theravance Biopharma R&D Ip, Llc Methods of treating symptoms of gastroparesis using velusetrag
WO2019058393A1 (en) 2017-09-22 2019-03-28 Jubilant Biosys Limited HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PAD
FI3697785T3 (fi) 2017-10-18 2023-04-03 Jubilant Epipad LLC Imidatsopyridiiniyhdisteitä pad:n estäjinä
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
WO2019102494A1 (en) 2017-11-24 2019-05-31 Jubilant Biosys Limited Heterocyclic compounds as prmt5 inhibitors
SG11202008950PA (en) 2018-03-13 2020-10-29 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
KR20240132505A (ko) 2022-01-11 2024-09-03 수벤 라이프 사이언시스 리미티드 5-HT4 수용체 작용제로서의 피롤로[1,2-b]-2-피리다지논 화합물
WO2024061960A1 (en) 2022-09-20 2024-03-28 Alfasigma S.P.A. Velusetrag for use in the treatment of chronic intestinal pseudo-obstruction (cipo)

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321378A (en) * 1979-01-16 1982-03-23 Delalande S.A. 8-(5-Pyrimidinecarboxamide)nor-tropane derivatives
US4937247A (en) * 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
GB8527052D0 (en) * 1985-11-02 1985-12-04 Beecham Group Plc Compounds
NL8701682A (nl) * 1986-07-30 1988-02-16 Sandoz Ag Werkwijze voor het therapeutisch toepassen van serotonine antagonisten, aktieve verbindingen en farmaceutische preparaten die deze verbindingen bevatten.
DE3777805D1 (de) * 1986-11-21 1992-04-30 Glaxo Group Ltd Arzneimittel zur behandlung oder vorbeugung des entzugssyndromes.
GB8701022D0 (en) * 1987-01-19 1987-02-18 Beecham Group Plc Treatment
US5223511A (en) * 1987-09-23 1993-06-29 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
IT1231413B (it) 1987-09-23 1991-12-04 Angeli Inst Spa Derivati dell'acido benzimidazolin-2-osso-1-carbossilico utili come antagonisti dei recettori 5-ht
IT1226389B (it) * 1988-07-12 1991-01-15 Angeli Inst Spa Nuovi derivati ammidinici e guanidinici
US5017573A (en) * 1988-07-29 1991-05-21 Dainippon Pharmaceutical Co., Ltd. Indazole-3-carboxylic acid derivatives
EP0410509A1 (de) * 1989-07-25 1991-01-30 Duphar International Research B.V Substituierte 1H-Indazol-3-carboxamide
JPH045289A (ja) 1990-04-24 1992-01-09 Hokuriku Seiyaku Co Ltd アミド化合物
JP3122671B2 (ja) * 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
HU211081B (en) * 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
DE69113284T2 (de) * 1990-12-28 1996-02-22 Kyowa Hakko Kogyo Co., Ltd., Tokio/Tokyo Chinolinderivat.
PT100785A (pt) 1991-08-20 1994-04-29 Smithkline Beecham Plc Utilizacao de compostos, por exemplo indole-3-carboxilatos, para a producao de medicamentos, compostos ai utilizados e composicoes farmaceuticas que os contem.
AU2491092A (en) * 1991-09-12 1993-04-05 Smithkline Beecham Plc Azabicyclic compounds as 5-ht4 receptor antagonists
MX9305947A (es) * 1992-09-29 1994-06-30 Smithkline Beecham Plc Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
WO1994012497A1 (en) * 1992-11-20 1994-06-09 Taisho Pharmaceutical Co., Ltd. Heterocyclic compound
TW251287B (de) 1993-04-30 1995-07-11 Nissei Co Ltd
GB9310582D0 (en) * 1993-05-22 1993-07-07 Smithkline Beecham Plc Pharmaceuticals
AU679336B2 (en) * 1994-02-28 1997-06-26 Taisho Pharmaceutical Co., Ltd. Heterocyclic compound
US5864039A (en) * 1994-03-30 1999-01-26 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compounds and use thereof as medicaments
GB9406857D0 (en) * 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
JP3829879B2 (ja) * 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
JP3796766B2 (ja) * 1994-05-18 2006-07-12 大正製薬株式会社 アルキル置換キノリンカルボン酸誘導体
CA2160420A1 (en) * 1994-10-20 1996-04-21 Haruhiko Kikuchi 5-ht4 receptor agonists
JP3829880B2 (ja) 1994-12-27 2006-10-04 大正製薬株式会社 化学中間体
US5612339A (en) * 1995-01-17 1997-03-18 Trustees Of The University Of Pennsylvania 2-Hydroxy-3-aminopropylsulfonamides
IT1275903B1 (it) * 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
KR19990022096A (ko) * 1995-05-31 1999-03-25 쇼다 오사무 모노시클릭 아미노기를 갖는 인다졸 유도체
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
ES2109190B1 (es) 1996-03-22 1998-07-01 Univ Madrid Complutense Nuevos derivados de bencimidazol con afinidad por los receptores serotoninergicos 5-ht /5-ht
IT1291569B1 (it) * 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici
TW402591B (en) * 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US6069152A (en) * 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
US5914405A (en) * 1997-10-07 1999-06-22 Eli Lilly And Company Process for preparing 3-substituted indazoles
FR2769915B1 (fr) 1997-10-21 2000-10-13 Synthelabo Derives d'indazole tricycliques, leur preparation et leur application en therapeutique
IT1298271B1 (it) 1998-02-18 1999-12-20 Boehringer Ingelheim Italia Esteri ed ammidi dell'acido 2-oxo-2,3-diidro-benzimidazol-1- carbossilico
HUP0101511A3 (en) * 1998-04-28 2002-12-28 Dainippon Pharmaceutical Co 1-[(1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
ATE357443T1 (de) * 1998-09-10 2007-04-15 Hoffmann La Roche Dihydrobenzodioxincarbonsäureamid- und ketonderivate als 5-ht4-rezeptorantagonisten
TW570920B (en) * 1998-12-22 2004-01-11 Janssen Pharmaceutica Nv 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders
FR2792318B1 (fr) 1999-04-16 2001-06-15 Synthelabo Derives d'indazole, leur preparation et leur application en therapeutique
EP1173168A2 (de) * 1999-04-28 2002-01-23 Respiratorius AB Verbindung zur verwendung als medikament zur behandling von krankheiten die durch fehlregulation der bronchienkontraktion gekennzeicht sind
ES2154605B1 (es) 1999-09-14 2001-11-16 Univ Madrid Complutense Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3
IT1313625B1 (it) * 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
AU2002212888A1 (en) * 2000-11-01 2002-05-15 Respiratorius Ab Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
US6624162B2 (en) * 2001-10-22 2003-09-23 Pfizer Inc. Imidazopyridine compounds as 5-HT4 receptor modulators
MXPA03000145A (es) * 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
US6696468B2 (en) * 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
JP2006502180A (ja) 2002-09-20 2006-01-19 ファイザー株式会社 ５−ｈｔ４レセプターモジュレーターとしてのｎ−置換されたピペリジニル−イミダゾピリジン化合物
DOP2003000703A (es) * 2002-09-20 2004-03-31 Pfizer Compuestos de imidazopiradina como agonistas del receptor 5-ht4
EP1620435A1 (de) * 2003-04-21 2006-02-01 Pfizer Inc. Imidazopyridine mit aktivität als 5-ht4 rezeptor agonist und 5ht3 rezeptor antagonist
US7652040B2 (en) 2003-06-19 2010-01-26 Janssen Pharmaceutica N.V. Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists
JO2478B1 (en) 2003-06-19 2009-01-20 جانسين فارماسوتيكا ان. في. (Aminomethyl) -biperidine benzamides as 5 HT4 antagonists
AU2004268840B9 (en) 2003-09-03 2011-02-03 Pfizer Inc. Benzimidazolone compounds having 5-HT4 receptor agonistic activity
JP4704353B2 (ja) 2003-11-24 2011-06-15 ファイザー株式会社 ５−ｈｔ４受容体アゴニスト活性を有するキノリンカルボン酸化合物
ATE388146T1 (de) 2004-01-29 2008-03-15 Pfizer 1-isopropyl-2-oxo-1,2-dihydropyridin-3- carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor
TW200533348A (en) * 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
WO2005092882A1 (en) 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
WO2006052640A1 (en) 2004-11-05 2006-05-18 Theravance, Inc. 5-ht4 receptor agonist compounds
JP5042028B2 (ja) * 2004-11-05 2012-10-03 セラヴァンス， インコーポレーテッド キノリノン−カルボキサミド化合物
EP1831211B1 (de) 2004-12-22 2010-06-02 Theravance, Inc. Indazolcarbonsäureamidverbindungen
EA013567B1 (ru) 2005-03-02 2010-06-30 Тереванс, Инк. Хинолиноновые соединения в качестве агонистов рецептора 5-ht
TWI377206B (en) 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
JP5086248B2 (ja) 2005-06-07 2012-11-28 セラヴァンス， インコーポレーテッド ５−ｈｔ４受容体アゴニストとしてのベンゾイミダゾロン−カルボキサミド化合物

Also Published As

Publication number Publication date
RU2394033C2 (ru) 2010-07-10
AR050407A1 (es) 2006-10-25
US7375114B2 (en) 2008-05-20
EP1735304B1 (de) 2009-01-07
ES2320907T3 (es) 2009-05-29
AU2005233560B2 (en) 2012-04-05
JP2007532546A (ja) 2007-11-15
US8575192B2 (en) 2013-11-05
HRP20090162T1 (en) 2009-05-31
JP2008174569A (ja) 2008-07-31
CY1108908T1 (el) 2014-07-02
CA2561558A1 (en) 2005-10-27
US9630960B2 (en) 2017-04-25
PT1735304E (pt) 2009-03-27
HK1099019A1 (en) 2007-08-03
KR101167296B1 (ko) 2012-07-23
ATE420088T1 (de) 2009-01-15
US9353106B2 (en) 2016-05-31
US20100311979A1 (en) 2010-12-09
US20080176895A1 (en) 2008-07-24
US7592355B2 (en) 2009-09-22
BRPI0509761A (pt) 2007-10-16
CA2561558C (en) 2013-06-18
US20170334901A1 (en) 2017-11-23
MY155036A (en) 2015-08-28
TWI351282B (en) 2011-11-01
US20150291580A1 (en) 2015-10-15
US7763637B2 (en) 2010-07-27
US20070270457A1 (en) 2007-11-22
US8163920B2 (en) 2012-04-24
NO20065112L (no) 2006-12-08
CN1946719A (zh) 2007-04-11
ZA200608363B (en) 2008-05-25
BRPI0509761B1 (pt) 2018-07-31
CN100569771C (zh) 2009-12-16
IL178086A0 (en) 2006-12-31
NZ549941A (en) 2010-09-30
WO2005100350A8 (en) 2006-12-07
US9873692B2 (en) 2018-01-23
DE602005012249D1 (de) 2009-02-26
RU2006139053A (ru) 2008-05-20
JP4944012B2 (ja) 2012-05-30
SI1735304T1 (sl) 2009-06-30
TW200536540A (en) 2005-11-16
AU2005233560A1 (en) 2005-10-27
BRPI0509761B8 (pt) 2021-05-25
MXPA06011398A (es) 2006-12-20
US20050228014A1 (en) 2005-10-13
US20120264779A1 (en) 2012-10-18
EP1735304A1 (de) 2006-12-27
PL1735304T3 (pl) 2009-06-30
US8962653B2 (en) 2015-02-24
NO337126B1 (no) 2016-01-25
US20140163063A1 (en) 2014-06-12
KR20070015423A (ko) 2007-02-02
US20160376264A1 (en) 2016-12-29
IL178086A (en) 2011-09-27
WO2005100350A1 (en) 2005-10-27
DK1735304T3 (da) 2009-04-20

Similar Documents

Publication Publication Date Title
MA28559B1 (fr) Composes de quinolinone-carboxamide en tant qu&#39;agonistes du recepteur de 5-ht4
FR23C1039I1 (fr) Derives de piperidinone carboxamide azaindane en tant qu&#39;antagonistes du recepteur cgrp
DE602005027307D1 (de) Arylanilinderivate als agonisten des beta2-adrenergen rezeptors
MA29071B1 (fr) Amino-pyridimidine 2, 6-substituee-4-monosubstituee en tant qu&#39;antagonistes de recepteur de la prostaglandine d2
MA28815B1 (fr) Derives de indole-2-carboxamidine utilises comme antagonistes du recepteur nmda
DE602006004768D1 (de) Carboxamid derivate als muskarin rezeptor antagonisten
NO20050429D0 (no) Substituert kinolin-CCR5-reseptorantagonister
MA27680A1 (fr) Derives de 4-phenyl-pyridine en tant qu&#39;antagonistes du recepteur de la neurokinine-1
ATE495167T1 (de) Piperidin-4-yl-pyridazin-3-yl-aminderivate als schnell dissoziierende antagonisten des dopamin-2-rezeptors
MA29080B1 (fr) Derives de la quinuclidine et leur utilisation en tant qu&#39;antagonistes du recepteur m3 muscarinique
ATE421511T1 (de) Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
ATE429428T1 (de) Indanderivate als antagonisten des mch-rezeptors
ATE509927T1 (de) Indolderivate als s1p1-rezeptor-agonisten
ATE485270T1 (de) 2-phenylindole als antagonisten des prostaglandin-d2-rezeptors
MA28089A1 (fr) AGONISTES ETHYLAMINO AMINOSUBSTITUES DU RECEPTEUR ß2 ADRENERGIQUE
IS7238A (is) Meðferðarfræðileg kínólínefnasambönd með eiginleika 5-HT-mótlyfs
ATE481405T1 (de) Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors
ATE555111T1 (de) Chinuclidinol-derivate als muscarinrezeptor- antagonisten
BRPI0717912A2 (pt) &#34;dispositivo de vigilância&#34;
ATE377419T1 (de) Substituierte 4-alkoxyoxazol derivate als ppar agonisten
DK1899324T3 (da) Benzimidazolcarboxamid-forbindelser som 5-HT4-receptoragonister
ATE477243T1 (de) 2-aminochinoline als 5-ht(5a)- rezeptorantagonisten
ATE518834T1 (de) 2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten
MA28602B1 (fr) Pyridin-4-yl-ethynyl-imidazoles et pyrazoles en tant qu&#39;antagonistes des recepteurs mglur5
MA28819B1 (fr) Derives amides d&#39;acide kynurenique utilises en tant qu&#39;antagonistes de recepteurs de nr2b